New Angiogenesis Inhibitors Derived from Fumagillin

Angiogenesis, the formation of new blood vessels, is involved in the pathogenesis of a number of common human diseases, including cancer, diabetic retinopathy, rheumatoid arthritis, and macular degeneration. Inhibitors of angiogenesis can be used for the treatment of all aforementioned disease conditions as well as other angiogenesis-dependant illnesses. The fumagillin family of natural products have previously been reported to be potent inhibitors of angiogenesis. Researchers at JHU have discovered a new structural class of fumagillin analogs that possess anti-angiogenic activity with significantly lower toxicity than TNP-470. Description (Set) Proposed Use (Set) The novel compounds inhibit angiogenesis in vivo and could be used for their therapeutic effect on angiogenesis-dependant human diseases.

Inventor(s): Liu, Jun

Type of Offer: Licensing



« More Medical Patents

---